Conexeu Sciences Inc.
CNXUHealthcare|Biotechnology|US
$2.26
+0.14 (+6.60%)
About
Conexeu Sciences Inc. specializes in pioneering regenerative biomaterials intended for various medical fields, including wound management, dental practices, and aesthetic medicine. The enterprise began operations on November 2, 2022, co-founded by Claudia Chavez-Munoz, David R. Bogart, and Ryan Hartwell, and operates from its primary office in Reno, Nevada.
Stock Price
-82.7%(1Y)
1M
-34.5%
3M
-72.0%
6M
-82.7%
YTD
-82.7%
1Y
-82.7%
3Y
-82.7%
5Y
-82.7%
Pipeline Summary
0 total trials0
Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
Key Facts
Market Cap$69.7M
Employees4
CEOMiles Harrison
IPO DateMay 21, 2026
Beta0.51
52-Week Range$2.07 – $18.79
Avg Volume245,589
ExchangeNASDAQ
Websitewww.conexeu.com
Ownership
Float53.4%
Shares Outstanding30.8M
Recent Insider Trades
Purcell Lynn SebastianBUY
Oct 15, 2026166,666 shares @ $3.00
Purcell Lynn SebastianBUY
Oct 15, 2026166,666 shares @ $3.00
Bogart David RobertOPTION EX.
Sep 25, 2026750,000 shares @ $0.00
Bogart David RobertOPTION EX.
Sep 25, 2026750,000 shares @ $0.00
Sharpe Jeffrey NathanOPTION EX.
Sep 14, 2026500,000 shares @ $0.00
Recent News
Conexeu Sciences Announces $5 Million Private Placement Led by Existing Shareholders, Management and Directors
Oct 15, 2026 · globenewswire.com
Conexeu Sciences Advances Ten Minute Tissue™ Toward Planned FDA 510(k) Submission
Oct 6, 2026 · globenewswire.com
A Wave of Weight-Loss Drugs Is Quietly Creating a Multi-Billion-Dollar Opportunity That Aesthetic Medicine Is Racing to Capture
Sep 1, 2026 · gurufocus.com
Conexeu Sciences Sets September and October 2026 Conference Schedule
Sep 1, 2026 · globenewswire.com
Conexeu Sciences Sees a New Category Forming in Medical Aesthetics as Research Turns to Regeneration
Aug 18, 2026 · globenewswire.com
Data last updated: Nov 9, 2026, 04:03 AM